Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06179069 · ClinicalTrials.gov registry record · Phase 1
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
A Phase 1 study of SCLC, sponsored by Zai Lab (Shanghai) Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 112
- Enrollment target
- 20
- Study locations
NCT06179069 is a Phase 1 study of SCLC that is actively recruiting participants, run by Zai Lab (Shanghai) Co.. The registered enrollment target is 112 participants, below the 184-participant average among 10 other SCLC trials with a reported enrollment target (39% lower). The trial reports 20 study locations across 20 states.
The verdict
NCT06179069, a Phase 1 study of SCLC, is actively recruiting participants, sponsored by Zai Lab (Shanghai) Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 112 participants
- Enrollment target
- 20
- Study locations
Study Summary
An open-label, multicenter study of ZL-1310 as a single agent and in combination with Atezolizumab (with and without Carboplatin) to evaluate the safety, efficacy, and pharmacokinetics in subjects with small cell lung cancer
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Atezolizumab
- DRUG ZL-1310
Study Locations (20)
California
- Zai Lab Site 2005 - Duarte
Connecticut
- Zai Lab Site 2030 - New Haven
Florida
- Zai Lab Site 2026 - Sarasota
Michigan
- Zai Lab Site 2013 - Detroit
New Jersey
- Zai Lab Site 2001 - Hackensack
New York
- Zai Lab Site 2002 - Buffalo
North Carolina
- Zai Lab Site 2018 - Durham
Ohio
- Zai Lab Site 2024 - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2024-01-23 |
| Est. Completion | 2027-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06179069
The ClinicalTrials.gov registry entry for NCT06179069 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 184-participant average among 10 other SCLC trials with a reported enrollment target (39% lower). The listed sponsor is Zai Lab (Shanghai) Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with SCLC appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.
NCT06179069 reports 20 study locations spanning 20 distinct geographic areas - top geographies include California, Connecticut, Florida.
Frequently Asked Questions
What is clinical trial NCT06179069 about?
NCT06179069 is a clinical study titled "A Study of ZL-1310 in Subjects With Small Cell Lung Cancer". An open-label, multicenter study of ZL-1310 as a single agent and in combination with Atezolizumab (with and without Carboplatin) to evaluate the safety, efficacy, and pharmacokinetics in subjects with small cell lung cancer
What is the current status of trial NCT06179069?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 112 participants. The study started on 2024-01-23. Estimated completion is 2027-07-31.
What conditions does trial NCT06179069 study?
This clinical trial studies the following conditions: SCLC.
What interventions are being tested in trial NCT06179069?
The interventions under investigation include: Carboplatin (DRUG), Atezolizumab (DRUG), ZL-1310 (DRUG).
Who is sponsoring clinical trial NCT06179069?
This trial is sponsored by Zai Lab (Shanghai) Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06179069 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Michigan, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SCLC
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
RECRUITING · Phase 1
-
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
RECRUITING · Phase 1
-
SLV-154 Treatment of Metastatic Solid Tumors
RECRUITING · Phase 1
-
Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Study of Oral MRT-2359 in Selected Cancer Patients
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.